Prevalence and Factors Associated With Financial Toxicity Among Patients With GI Cancer in Pakistan. Read the full article. bit.ly/4v3vYO4 #GastrointestinalCancer #gicsm

🚨 New data further strengthen the case for dual HER2 blockade in gastroesophageal cancer. HERIZON-GEA-01 showed that zanidatamab plus chemotherapy ± tislelizumab improved survival in HER2-positive gastroesophageal adenocarcinoma. Read more 📰 onclive.com/view/zanidatamab… #gicsm #oncology

ASCO 2026: Tumores Hepatobiliopancreáticos | Dr Ricardo Carvalho Quais foram as novidades da #ASCO26 para os tumores hepatobiliopancreáticos? Dr Ricardo Carvalho apresenta os destaques, com moderação do Dr Fábio Kater #MOCnaASCO #GIcsm @rcarvalhoonco mocbrasil.com/canais-moc/con…

📊 HERIZON-GEA-01 demonstrated impressive efficacy—but what are the most important toxicity management considerations? In the video below 🎥, Geoffrey Ku, MD, @MSKCancerCenter explains why proactive diarrhea prevention and management will be critical as clinicians gain experience with zanidatamab plus tislelizumab in HER2 GEA.⬇️ #gicsm #oncology #ASCO26 @ASCO

ASCO 2026: Câncer de Esôfago e Estômago | Dr Lucas dos Santos O Dr Lucas dos Santos revisa os destaques da #ASCO26 em tumores esofagogástricos. Ao final, acompanhe o debate sobre a prática clínica com Dr Fabio Kater #MOCnaASCO #GIcsm @AntonioDiasJr86 mocbrasil.com/canais-moc/con…

ASCO 2026: Tumores Colorretais | Dr Felipe Moraes Nesta aula, o Dr Felipe Moraes apresenta os highlights da #ASCO26 em Tumores Colorretais, com participação do Dr Fábio Kater Acompanhe a discussão completa #CRC #GIcsm @rcarvalhoonco @AntonioDiasJr86 mocbrasil.com/canais-moc/con…

Here are key cancer awareness dates and months to note in 2026 across oncology. Explore more about oncology conferences, top trials, and reactions from oncologists: clin.larvol.com #LARVOL #Oncology #CancerCare #CancerAwarenes #BreastCancer #BCSM #LungCancer #LCSM #GICancer #GICSM #GUCancer #GUCSM #Melanoma #Lymphoma #Leukemia #MultipleMyeloma #HEMSM #MMSM #LEUSM #LYMSM #HeadAndNeckCancer #KindneyCancer #ColorectalCancer #BloodCancer

Ahead of @ASCO 2026, we asked leading AI models to identify the GI cancer trials most likely to shape the meeting. We then compared those predictions with engagement on 𝕏 to see where AI and the oncology community aligned and where they diverged. 👉 Strong alignment at the top: Several studies were consistently identified across all four AI models and also generated significant online attention: ▶️ RASolute 302 (4.2M views) ▶️ BREAKWATER (185K views) ▶️ EMERALD-3 (100K views) Together, they highlight continued interest in KRAS-targeted therapies, biomarker-driven colorectal cancer treatment, and combination immunotherapy approaches in HCC. 👉 Where buzz outpaced AI expectations: → CIRCULATE (78K views), reflecting strong interest in ctDNA-guided treatment strategies in colon cancer → ATTRACTION-6 (70K views), highlighting ongoing attention around dual-checkpoint approaches in gastric cancer → HERIZON-GEA-01 (49K views), driven by interest in next-generation HER2-targeted combinations 👉 Themes that resonated across AI and the community: ▶️ Precision oncology remains a major focus across GI cancers ▶️ KRAS, BRAF, FGFR2, HER2, and MET-directed therapies continue to attract attention ▶️ ctDNA-guided treatment decisions are gaining momentum in early-stage disease ▶️ Combination immunotherapy strategies remain a key area of interest in HCC and upper GI cancers 👉 Where AI and the community diverged: AI models tended to prioritize late-stage studies with clear practice-changing potential and strong biomarker rationale, while the community also gravitated toward ctDNA-guided approaches and emerging targeted therapies with novel mechanisms of action. Which GI trial from ASCO 2026 generated the most discussion in your network? Explore more insights and conference data from #ASCO26 👉 clin.larvol.com/conference/a… #LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology #GIOncology #GICancer #GICSM #GastrointestinalCancer | @ArndtVogel | @CathyEngMD | @GillSharlene | @rachnatshroff | @MPishvaian

Ahead of @ASCO 2026, we asked leading AI models to forecast outcomes for major GI cancer trials and compared those predictions with the data presented at ASCO 2026. Overall accuracy: ➡️ Median survival: R² = 0.96 (n=6) ➡️ Hazard ratios: R² = 0.82 (n=3) Dataset: ➡️ 3 major GI cancer trials ➡️ 16 predictions ➡️ 3 AI-modeled KM curves ➡️ Claude served as the final judge Where AI got it right: EMERALD-3 (PFS, HCC) ▶️ AI: HR 0.65 ▶️ Actual: HR 0.70 EMERALD-3 (OS, HCC) ▶️ AI: HR 0.77 ▶️ Actual: HR 0.84 (NS) NCT06008119 (ORR, BRAF-mutant CRC) ▶️ AI: ~39% ▶️ Actual: 37.1% Where AI underestimated benefit: NCT06008119 (PFS, BRAF-mutant CRC) ▶️ AI: HR 0.62 ▶️ Actual: HR 0.37 This was the largest prediction gap in the GI dataset. Key takeaways: ✅ AI correctly identified the direction of benefit across the major GI readouts ✅ Accuracy was strongest for response-based endpoints and broad efficacy signals ✅ The largest miss came in BRAF-mutant colorectal cancer, where AI predicted success but significantly underestimated the magnitude of benefit ✅ Unlike some other disease areas, GI produced few major directional misses; most discrepancies involved the size of the treatment effect AI continues to show value in anticipating broad clinical outcomes, but estimating the magnitude of benefit remains challenging when therapies outperform historical expectations. What stood out to you most from the ASCO 2026 GI cancer data? Which result diverged most from expectations? Explore more insights and conference data from #ASCO26 👉 clin.larvol.com/conference/a… #LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology #GICancer #GastrointestinalCancer #GICSM #LiverCancer #ColonCancer #ColorectalCancer | @ArndtVogel | @pashtoonkasi | @CathyEngMD | @Erman_Akkus | @GIcancerDoc

Most active cancer institutes in 𝕏 during @ASCO 2026. Ranked by views of oncologist posts on clinical trials. Explore more insights and conference data from #ASCO26 👉 clin.larvol.com/conference/a… #LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology #LungCancer #SCLC #esSCLC #NSCLC #LCSM #BreastCancer #TNBC #BCSM #GUCancer #GUCSM #GenitourinaryCancer #KidneyCancer #BladderCancer #ProstateCancer #GICancer #GastrointestinalCancer #GICSM #ColorectalCancer #GastricCancer #LiverCancer #PancreaticCancer #Hematology #Leukemia #Lymphoma #MultipleMyeloma #BloodCancer #HemeOnc #MMSM #LEUSM #LYMSM | @RenovaHospitals | @DanaFarber | @Intermountain | @AnkaraUni | @UTMDAnderson | @juntendo_univ | @NorthwellHealth | @fortis_hospital | @ONealCancerUAB | @Georgetown | @univmiami | @ClevelandClinic | @BCCancer | @UHhospitals | @InstitutoRoffo | @NHSBartsHealth | @UTSWMedCenter | @UIHealth | @DrRishabhOnco | @PTarantinoMD | @DrChoueiri | @marklewismd | @Dave_Gill_SLC | @HHorinouchi | @shimoi_oncology | @AndreaNecchi | @BianchiniGP | @DrYukselUrun | @DrMirallas | @DrBarbiOnc | @Erman_Akkus | @lungoncdoc | @M_Torasawa | @GIMedOnc | @SuyogCancer | @ADesaiMD | @StephenVLiu | @coffman_kelley | @Latinamd | @AmandaNizamMD | @GlopesMd | @dr_yakupergun | @jamecancerdoc | @ronanhsieh | @GillSharlene | @DrSpratticus | @MamMa_mimumemo

Top trending women GI cancer oncologists on 𝕏 during @ASCO 2026. Ranked by views of oncologist posts on clinical trials. Explore more insights and conference data from #ASCO26 👉 clin.larvol.com/conference/a… #LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology #GICancer #GastrointestinalCancer #GICSM #ColorectalCancer #GastricCancer #LiverCancer #PancreaticCancer | @GillSharlene | @coffman_kelley | @DraMartinezLago | @NiuSanford | @DrAngelaLamarca | @CathyEngMD | @graokane | @rutikamehtaMD | @rachnatshroff | @drallysonocean

Reactions on top trending GI Cancer trials during @ASCO 2026, curated by @Larvol CLIN. Explore more insights and conference data from #ASCO26 👉 clin.larvol.com/conference/a… #LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology #GICancer #GastrointestinalCancer #GICSM #ColorectalCancer #GastricCancer #LiverCancer #PancreaticCancer | @marklewismd | @Erman_Akkus | @GIMedOnc | @ronanhsieh | @GillSharlene | @DaisukeKotani | @coffman_kelley | @DraMartinezLago | @ryanhuey | @ArndtVogel

Top trending companies on X from @ASCO 2026 for GI cancer, curated by @LARVOL CLIN. Explore more insights and conference data from #ASCO26 👉 clin.larvol.com/conference/a… #LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology #GICancer #GastrointestinalCancer #GICSM #ColorectalCancer #GastricCancer #LiverCancer #PancreaticCancer | @marklewismd | @Erman_Akkus | @GIMedOnc | @ronanhsieh | @GillSharlene | @DaisukeKotani | @coffman_kelley | @DraMartinezLago | @ryanhuey | @ArndtVogel

Top trending GI cancer oncologists on 𝕏 during @ASCO 2026. Ranked by views of oncologist posts on clinical trials. Explore more insights and conference data from #ASCO26 👉 clin.larvol.com/conference/a… #LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology #GICancer #GastrointestinalCancer #GICSM #ColorectalCancer #GastricCancer #LiverCancer #PancreaticCancer | @marklewismd | @Erman_Akkus | @GIMedOnc | @ronanhsieh | @GillSharlene | @DaisukeKotani | @coffman_kelley | @DraMartinezLago | @ryanhuey | @ArndtVogel

Top trending GI cancer trials on 𝕏 and key results from @ASCO 2026. Ranked by views of oncologist posts on clinical trials. Explore more insights and conference data from #ASCO26 👉 clin.larvol.com/conference/a… #LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology #GICancer #GastrointestinalCancer #GICSM #ColorectalCancer #GastricCancer #LiverCancer #PancreaticCancer | @marklewismd | @Erman_Akkus | @GIMedOnc | @ronanhsieh | @GillSharlene | @DaisukeKotani | @coffman_kelley | @DraMartinez | @Lagoryanhuey | @ArndtVogel

🚨 LINEUP UPDATE! 🚨 We've added 2 new experts in GU cancer and myeloma to our #ASCO26 OncLive takeover roster to bring you even MORE real-time reactions straight from the conference floor.💥 NOW featuring: NEW❗️@QianJanieQin on X @HundalJasmin on LinkedIn @HannahRAbrams on X @SaraNunneryMD on Instagram NEW❗️@DottorClaudio on X @SKamath_MD on X And@Jonathanwlee23and@Jani_Chinmayon X Our social media takeovers kick off TODAY, so be sure to check out the full schedule below 👇 and follow along on X, Instagram, and/or LinkedIn. 👀 @ASCO #lcsm #bcsm #sarcsm #gicsm #mmsm #prcsm #blcsm

GLP-1 Receptor Agonists & colorectal cancer at #ASCO26: 11 abstracts, with 3 poster abstracts independently signaling a survival (and toxicity) benefit when added to standard therapy. All retrospective EHR cohorts (TriNetX/Blue Diamond). Propensity Score Matching (PSM) helps, but residual confounding, healthy-user bias and follow-up imbalance are real limitations. Still, a "consistent" directional signal across stages I–IV, with ICI and with cytotoxic chemo. Worth prospective testing. #CRCSM #GIcsm A quick #GIonc read 🧵 (See below)

🚨 Newly published in @NEJM: HERIZON-GEA-01 data show #zanidatamab plus chemotherapy ± tislelizumab significantly improved survival in HER2-positive GEA. 📊 Our latest coverage features exclusive insights from Geoffrey Ku, MD, of @MSKCancerCenter on the implications of this landmark publication, plus a preview of upcoming PD-L1 subgroup analyses set to be presented at #ASCO26. 🔬 Read more here 📰: onclive.com/view/zanidatamab… #gicsm #oncology #gastriccancer #esophagealcancer

As GI oncology discussions accelerate ahead of @ASCO 2026, we asked leading AI models to identify the trials most likely to drive attention at this year’s meeting. There was particularly strong consensus around ATTRACTION-6, CIRCULATE, EMERALD-3, HERIZON-GEA-01, and RASolute 302—highlighting continued momentum for immunotherapy combinations, ctDNA-guided strategies, targeted therapies, and biomarker-driven treatment approaches across GI cancers. The list underscores key themes shaping the field: ▶️ Expansion of immunotherapy-based combinations in gastric, esophageal, and liver cancers ▶️ Growing interest in ctDNA-guided treatment decision-making in colon cancer ▶️ Continued development of targeted therapies in KRAS-, FGFR2-, and BRAF-driven tumors ▶️ Increased focus on biomarker-selected approaches across GI malignancies ▶️ Novel ADC and combination strategies in upper GI cancers Notable studies include: • EMERALD-3 evaluating tremelimumab durvalumab-based combinations in HCC • CIRCULATE exploring ctDNA-guided adjuvant treatment strategies in stage II colon cancer • HERIZON-GEA-01 advancing zanidatamab-based therapy in HER2 gastric/GEJ cancer • RASolute 302 studying daraxonrasib in metastatic pancreatic cancer • BREAKWATER evaluating targeted combinations in BRAF V600E-mutant mCRC Together, these studies reflect how GI oncology continues to move toward more personalized, biomarker-informed, and combination-driven treatment strategies heading into ASCO 2026. Which GI cancer trial are you watching most closely? Explore more insights and conference data from #ASCO26 👉 clin.larvol.com/conference/a… #LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology #GIOncology #GICancer #GICSM #GastrointestinalCancer | @ArndtVogel | @CathyEngMD | @GillSharlene | @rachnatshroff | @MPishvaian

Updated HERIZON-GEA-01 data from @ASCO 2026 in 1L HER2 Unresc/LA/m GC/GEJA landscape from Dr. Daniel Lin (@DanielLinMD) 👉 x.com/SuyogCancer/status/200… Updated Landscape 👉 clin.larvol.com/landscape/43… Explore more insights and conference data from #ASCO26 👉 clin.larvol.com/conference/a… #LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology #HERIZONGEA01 #GastricCancer #GastroesophagealJunctionCancer #GICSM | @SuyogCancer | @marklewismd | @CathyEngMD | @Erman_Akkus | @GillSharlene | @DaisukeKotani